

## DFEND study

---

A randomised, double-blind, placebo-controlled, parallel-group trial of Vitamin D supplementation compared to placebo in people presenting with their First Episode of psychosis Neuroprotection Design (DFEND)

### Justification of missing Results:

Sponsor Protocol Code:	DFEND
EudraCT Number:	2014-002639-32
REC Number:	14/LO/1588
Investigational Drugs (IMPs):	Cholecalciferol (Vigantol® oil)
Indication:	First Episode Psychosis
Development Phase:	Phase II
Study Begin (FPFV):	19/01/2016
Study End (LPLV):	13/12/2019
Co-sponsors:	King's College London and South London and Maudsley NHS Foundation Trust
Co-sponsor contact details:	King's Health Partners Clinical Trials Office Great Maze Pond, London SE1 9RT Tel: 020 7188 5732 Email: amy.holton@kcl.ac.uk
Chief Investigator:	Name: Dr Fiona Gaughran Address: South London & Maudsley NHS Trust, National Psychosis Unit, Royal Bethlem Hospital, Monks Orchard Rd, Beckenham, BR3 3BX Telephone: 07794594220 Email: fiona.p.gaughran@kcl.ac.uk

Due to COVID-19 pandemic the start of the data analysis was delayed, so the analysis is not yet completed. All results of the analysis will be available by end of February 2021. The trial recruited 149 participants from 5 sites over the course of 47 months.